New thiazolyl-pyrazoline derivatives bearing nitrogen mustard as potential antimicrobial and antiprotozoal agents. 2020

Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
Grupo de Investigación de Compuestos Heterocíclicos, Departamento de Química, Universidad del Valle, Cali, Colombia.

A new series of N-substituted pyrazoline derivatives 6a-g, 7a-g, 8a-g, and 9a-g was synthetized by reaction of hydrazine derivatives and chalcone-thiazole hybrids bearing nitrogen mustard 5a-g. The chalcones 5a-g were obtained by Claisen-Schmidt condensation of thiazole-2-nitrogen mustard 3 and selected acetophenones 4a-g. These new compounds 6/7/8/9a-g were screened for their antifungal activity against Cryptococcus neoformans, with IC50 values of 3.9-7.8 µg/ml for the N-3,5-dichlorophenyl pyrazolines 9e-g. Interestingly, those compounds show low cytotoxic effects toward erythrocytes (RBC). In addition, N-acetyl (6a,b) and N-formyl pyrazolines (7a, 7b, 7c, and 7g) showed inhibitory activity against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, and vancomycin-intermediate S. aureus, with the most important minimum inhibitory concentration values ranging from 31.25 to 125 µg/ml. Regarding the antiprotozoal activity, thiazolyl-pyrazolines 9g, 8f, and 7c display high activity against Plasmodium falciparum, Leishmania (V) panamensis, and Trypanosoma cruzi, with EC50 values of 11.80, 6.46, and 4.98 μM, respectively, and with 7c being approximately 2.6-fold more potent than benznidazole with a selectivity index of 1.61 on U-937 human cells, showing promising potential as a novel antitrypanosomal agent.

UI MeSH Term Description Entries
D007891 Leishmania A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi. Leishmania (Leishmania),Leishmania (Viannia),Leishmania leishmania,Leishmania viannia,Leishmania leishmanias,Leishmania viannias,Leishmanias,Leishmanias (Leishmania),Leishmanias (Viannia),leishmanias, Leishmania,viannias, Leishmania
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000083123 Vancomycin-Resistant Staphylococcus aureus Isolates of the Staphylococcus aureus that are resistant to the antibiotic VANCOMYCIN. The S. aureus becomes resistant by acquiring plasmids carrying genes for VANCOMYCIN RESISTANCE. Vancomycin‐intermediate S. aureus has low-level vancomycin resistance requiring an intermediate concentration of vancomycin between sensitive and resistant isolates. These S. aureus with reduced susceptibility to vancomycin and related GLYCOPEPTIDE antibiotics are often seen in HEALTHCARE ASSOCIATED INFECTIONS. Glycopeptide-Intermediate S. aureus,Glycopeptide-Intermediate Staphylococcus aureus,Glycopeptide-Resistant S. aureus,Glycopeptide-Resistant Staphylococcus aureus,Vancomycin-Intermediate S. aureus,Vancomycin-Intermediate Staphylococcus aureus,Vancomycin-Resistant S. aureus
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
October 2019, European journal of medicinal chemistry,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
June 2013, Archiv der Pharmazie,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
January 2013, Bioorganic & medicinal chemistry,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
September 2011, Bioorganic & medicinal chemistry letters,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
May 2019, Bioorganic & medicinal chemistry letters,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
October 2015, Molecules (Basel, Switzerland),
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
October 1999, Farmaco (Societa chimica italiana : 1989),
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
January 2024, International journal of molecular sciences,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
January 2024, Journal of biomolecular structure & dynamics,
Viviana Cuartas, and Sara M Robledo, and Iván D Vélez, and María Del Pilar Crespo, and Maximiliano Sortino, and Susana Zacchino, and Manuel Nogueras, and Justo Cobo, and Yulieth Upegui, and Tatiana Pineda, and Lina Yepes, and Braulio Insuasty
November 1976, Journal of pharmaceutical sciences,
Copied contents to your clipboard!